Skye Bioscience to Participate in Investment Conferences in February
03 févr. 2021 09h09 HE
|
Skye Bioscience, Inc.
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
19 janv. 2021 08h30 HE
|
Skye Bioscience, Inc.
San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th
15 janv. 2021 13h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary,...
Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
05 janv. 2021 08h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal
16 déc. 2020 08h30 HE
|
Emerald Bioscience, Inc.
Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San...
Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference
07 déc. 2020 08h45 HE
|
Emerald Bioscience, Inc.
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing...
Emerald Bioscience Provides Corporate Update
30 sept. 2020 08h30 HE
|
Emerald Bioscience, Inc.
Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection...
Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
03 sept. 2020 11h39 HE
|
Emerald Bioscience, Inc.
San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...
Emerald Bioscience Appoints Biotech Veteran Dr. Margaret Dalesandro to Board of Directors
13 août 2020 08h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of...
Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO
10 août 2020 08h30 HE
|
Emerald Bioscience, Inc.
Renewed team and capital focused on advancing lead compound for glaucoma into clinical development San Diego, Calif, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI)...